NICE guidance - Enzalutamide for treating hormone-sensitive metastatic prostate cancer

Last edited 07/2021 and last reviewed 11/2021

Enzalutamide plus androgen deprivation therapy (ADT) is recommended, within its marketing authorisation, as an option for treating hormone-sensitive metastatic prostate cancer in adults

Notes:

• enzalutamide (formerly known as MDV3100) is a targeted androgen-receptor inhibitor that competitively binds to the ligand-binding domain of the androgen receptor and inhibits androgen-receptor translocation to the cell nucleus, recruitment of androgen-receptor cofactors, and androgen-receptor binding to DNA
  • enzalutamide significantly decreased the risk of radiographic progression and death and delayed the initiation of chemotherapy in men with metastatic prostate cancer (2)

Reference:

• NICE (July 2021). Enzalutamide for treating hormone-sensitive metastatic prostate cancer
• Beer TM et al; PREVAIL Investigators. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014 Jul 31;371(5):424-33